VistaGen Therapeutics (VTGN) to Release Quarterly Earnings on Thursday

VistaGen Therapeutics (NASDAQ:VTGN) is anticipated to release its Q3 2026 results before the market opens on Thursday, February 12th. Analysts expect VistaGen Therapeutics to post earnings of ($0.51) per share and revenue of $0.14 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Thursday, February 12, 2026 at 5:00 PM ET.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The business had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.16 million. On average, analysts expect VistaGen Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

VistaGen Therapeutics Stock Performance

VTGN stock opened at $0.53 on Thursday. The stock has a market capitalization of $20.78 million, a PE ratio of -0.28 and a beta of 0.32. The company has a fifty day moving average of $1.69 and a 200-day moving average of $2.92. VistaGen Therapeutics has a one year low of $0.51 and a one year high of $5.14.

Hedge Funds Weigh In On VistaGen Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC purchased a new position in shares of VistaGen Therapeutics during the 1st quarter worth approximately $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in VistaGen Therapeutics during the 3rd quarter valued at $39,000. Millennium Management LLC acquired a new stake in VistaGen Therapeutics during the 3rd quarter valued at $73,000. Bank of America Corp DE increased its position in VistaGen Therapeutics by 1,068.0% during the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after buying an additional 19,331 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of VistaGen Therapeutics in the second quarter worth $69,000. Institutional investors and hedge funds own 78.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on VTGN shares. William Blair reaffirmed a “market perform” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Maxim Group restated a “hold” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Stifel Nicolaus lowered VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price objective on the stock. in a report on Wednesday, December 17th. Jefferies Financial Group reissued a “hold” rating and issued a $0.90 target price (down previously from $15.00) on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Finally, Wall Street Zen cut shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, VistaGen Therapeutics currently has an average rating of “Reduce” and a consensus target price of $0.95.

Key Stories Impacting VistaGen Therapeutics

Here are the key news stories impacting VistaGen Therapeutics this week:

• Neutral Sentiment: Context — VistaGen is a clinical‑stage biopharma focused on neuropsychiatric therapies; the class period cited by filings runs from April 1, 2024 through December 16, 2025. Small market cap and low recent prices can amplify downside moves.
• Negative Sentiment: Class action filed on behalf of VTGN purchasers for the period April 1, 2024–December 16, 2025; Robbins LLP is soliciting claimants and publicizing the suit (raises litigation risk and potential financial/management distraction). VTGN CLASS ACTION ALERT: Robbins LLP Urges Vistagen Therapeutics, Inc. Stockholders to Reach Out for Information About the Securities Class Action Lawsuit
• Negative Sentiment: Multiple investor‑rights firms (Levi & Korsinsky, Rosen, Bragar Eagel & Squire, Gross, Faruqi, Holzer, etc.) have issued notices urging investors to contact counsel and meet a March 16, 2026 lead‑plaintiff deadline — broad media outreach increases awareness and potential participation in the suit. VTGN INVESTOR ALERT — LEVI & KORSINSKY, LLP ANNOUNCES CLASS ACTION OVER ALLEGED MISLEADING STATEMENTS ABOUT CLINICAL TRIAL PROGRESS
• Negative Sentiment: Allegations specifically reference false/misleading statements or failures to disclose risks around the Phase 3 PALISADE‑3 fasedienol trial — if true, this targets core clinical development messaging and could affect investor confidence and potential future fundraising. Lead‑Plaintiff Deadline of March 16, 2026 in the Vistagen Therapeutics, Inc. (VTGN) Securities Class Action Announced by Holzer & Holzer, LLC

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.